They concluded that overexpression of CYP4Z1 and/or 4Z2P might enhance the transcriptional ERα activity, apoptosis, stemness, and resistance to tamoxifen of breast cancer cells. The gene discussed is CYP4Z1; the disease is breast carcinoma.